ArticleBMC psychology2026
Heterogeneous neurocognitive signatures in early childhood autism: a combined analysis of pharmacological treatment and gender.
Article in BMC psychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeAutism spectrum disorder (ASD) is characterized by marked heterogeneity in sensory processing, self-regulation, and executive functioning during early childhood. Pharmacological treatments are widely used to manage behavioral symptoms; however, their role in shaping multidomain neurocognitive profiles remains unclear. This study aimed to determine whether neurocognitive profiles differ as a function of pharmacological treatment type (antipsychotic, ADHD medication, or no medication) and gender children with ASD in early childhood.
methodsThis cross-sectional study included 350 children aged 4-6 years diagnosed with ASD. Participants were stratified into three groups based on current pharmacological treatment: antipsychotic-treated (n = 115), ADHD-medicated (n = 110), and medication-free (n = 125), with balanced gender distribution. Parents completed the Parent-Rated Sensory Reactivity Scale (ESRS), the Self-Regulation Skills Scale-Parent Form (SRSS-P), and the Childhood Executive Functioning Inventory-Parent Form (CEFI-P). Autism severity was assessed using the Childhood Autism Rating Scale (CARS). Group differences were examined using ANOVA, followed by correlation and multiple regression analyses.
resultsNeurocognitive profiles differed significantly across pharmacological treatment groups (p < 0.01). Children receiving antipsychotic medication exhibited higher sensory reactivity and greater autism severity, whereas those receiving ADHD medication showed greater impairments in executive functioning and self-regulation. Medication-free children consistently demonstrated the lowest levels of impairment. Gender showed a limited moderating effect, with some domain-specific differences observed across treatment groups. Correlation and regression analyses indicated that pharmacological treatment and gender were associated with variability in neurocognitive domains and overall autism severity (R² = 0.46).
conclusionsPharmacological treatment type and gender are important factors associated with heterogeneity in neurocognitive profiles in early childhood (4-6 years) ASD. These findings suggest that medication-related differences extend beyond behavioral symptom control and are linked to distinct sensory, regulatory, and executive functioning patterns. Clinically, this highlights the importance of considering treatment type and gender when interpreting neurodevelopmental profiles and when planning individualized, multidomain interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.